FMTX | Forma Therapeutics Holdings, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	19.98 - 20.01
52 Week Range	4.95 - 20.28
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	N/A
Average Volume	1,553,402
Shares Outstanding	N/A
Market Cap	957,686,583
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-06-19

Valuation
Profitability
Growth
Health
P/E Ratio	-5.24
Forward P/E Ratio	-1.31
EPS	-3.82
1YR Price Target	38.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	189
Country	USA
Website	FMTX

Forma Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. The firm's pipeline products are Etavopivat, FT-7051, FT-8225, and others.

FMTX's peers: RDUS

*Chart delayed

Analyzing fundamentals for FMTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see FMTX Fundamentals page.

Watching at FMTX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on FMTX Technicals page.